Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, has announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at a public offering price of US$7.35 per share. The gross proceeds to Alpine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Alpine, are expected to be approximately US$100 million. In addition, Alpine has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,040,900 shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering are being sold by Alpine. The offering is expected to close on or about September 23, 2022, subject to customary closing conditions.
Latham & Watkins LLP represents to underwriter’s in the offering with a corporate deal team led by Bay Area partners Brian Cuneo and Phillip Stoup, with Bay Area associates Casey Tong, Taimi Jacobson, and Chelsi DeTurk. Advice was also provided on tax matters by Bay Area partner Grace Lee, with Bay Area associate Alexander Farris; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Chad Jennings; on intellectual property matters by Bay Area partner Christopher Hazuka, with San Diego associates Robert Yeh and Kristina Funahashi; and on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with Bay Area associate Mitch Bennett.